{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:57:27Z","timestamp":1781153847154,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006143","name":"Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006143","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.neurobiolaging.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T02:01:17Z","timestamp":1493172077000},"page":"211.e9-211.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis"],"prefix":"10.1016","volume":"56","author":[{"given":"Priyam","family":"Narain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perumal","family":"Vivekanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.neurobiolaging.2017.04.011_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/21678421.2013.778571","article-title":"Genetic and epigenetic studies of amyotrophic lateral sclerosis","volume":"14","author":"Al-Chalabi","year":"2013","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib2","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.0000000000001159","article-title":"ATXN2 polyQ intermediate repeats are a modifier of ALS survival","volume":"84","author":"Chio","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/17482960802566824","article-title":"Prognostic factors in ALS: a critical review","volume":"10","author":"Chio","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneurol.2011.111","article-title":"Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis","volume":"68","author":"Daoud","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"Dejesus-hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib9","doi-asserted-by":"crossref","first-page":"1847.e15","DOI":"10.1016\/j.neurobiolaging.2012.02.004","article-title":"ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling","volume":"33","author":"FaGellera","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib10","doi-asserted-by":"crossref","first-page":"546.e1","DOI":"10.1016\/j.neurobiolaging.2014.07.037","article-title":"Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion","volume":"36","author":"Fratta","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbadis.2006.01.004","article-title":"Genetics of familial and sporadic amyotrophic lateral sclerosis","volume":"1762","author":"Gros-Louis","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib12","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/hmg\/ddr045","article-title":"Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients","volume":"20","author":"Lee","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib14","doi-asserted-by":"crossref","first-page":"209.e3","DOI":"10.1016\/j.neurobiolaging.2011.08.005","article-title":"The chromosome 9 ALS and FTD locus is probably derived from a single founder","volume":"33","author":"Mok","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib15","first-page":"1","article-title":"C9orf72 mutations may be rare in frontotemporal lobar degeneration patients in India","volume":"8421","author":"Mukherjee","year":"2015","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A\u00a0hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21- linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib17","doi-asserted-by":"crossref","first-page":"1601.e1","DOI":"10.1016\/j.neurobiolaging.2014.12.009","article-title":"A\u00a0small deletion in C9orf72 hides a proportion of expansion carriers in FTLD","volume":"36","author":"Rollinson","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib18","doi-asserted-by":"crossref","first-page":"2421.e13","DOI":"10.1016\/j.neurobiolaging.2014.04.016","article-title":"Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers","volume":"35","author":"van Blitterswijk","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib19","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1212\/WNL.0b013e31821f445b","article-title":"Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2","volume":"76","author":"Van Damme","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molmed.2013.09.001","article-title":"Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?","volume":"20","author":"Van den Heuvel","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib21","doi-asserted-by":"crossref","first-page":"1004.e17","DOI":"10.1016\/j.neurobiolaging.2011.09.025","article-title":"Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts","volume":"33","author":"Van Langenhove","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2016.11.079","article-title":"Analysis of C9orf72 repeat expansion in amyotrophic lateral sclerosis patients from North India","volume":"373","author":"Vats","year":"2017","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib23","doi-asserted-by":"crossref","first-page":"e105534","DOI":"10.1371\/journal.pone.0105534","article-title":"Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS\u2013a systematic review and meta-analysis of observational studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2017.04.011_bib24","doi-asserted-by":"crossref","first-page":"e17951","DOI":"10.1371\/journal.pone.0017951","article-title":"PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats","volume":"6","author":"Yu","year":"2011","journal-title":"PLoS One"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745801730132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745801730132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T18:32:15Z","timestamp":1537900335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019745801730132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":24,"alternative-id":["S019745801730132X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.04.011","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}